Would the Boehringer Ingelheim 1297.2 Study be right for you?

BI 1297.2 Study

Boehringer Ingelheim 1297.2 Study

The 1297.2 Study is an international clinical research study looking at a potential new treatment for rheumatoid arthritis (RA). The potential new treatment – an investigational medication – has been developed to be similar to an existing, approved treatment.

This approved treatment has been shown to improve some of the symptoms of RA, such as joint stiffness, swelling, and pain. The study will evaluate whether the investigational medication is as effective and as safe as the existing approved treatment for people with rheumatoid arthritis.

Can you help?

Doctors are currently enrolling patients who have been diagnosed with rheumatoid arthritis for the 1297.2 Study. Your participation in this clinical research study may help to advance our knowledge of the investigational medication, and may benefit other people with rheumatoid arthritis in the future.

Please click below to answer a few simple questions to find out whether you may be eligible to participate in the 1297.2 Study.

Could You Take Part?

This website contains information about the research study and provides an opportunity to answer a few simple questions to find out whether you may be eligible to participate at a local study center.